Valuation : Orexo AB

Market Cap 529M 55.26M 47.56M 44.74M 40.87M 76.46M 5.22B 76.67M 205M 2.68B 208M 203M 8.62B P/E 2026 *
-1.45x
P/E 2027 * -2.08x
Enterprise Value 424M 44.29M 38.11M 35.86M 32.76M 61.28M 4.18B 61.44M 164M 2.15B 166M 163M 6.91B EV / Sales 2026 *
22.3x
EV / Sales 2027 * 14.3x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day-1.59%
1 week-5.10%
Current month-5.10%
1 month+1.50%
3 months-21.25%
6 months-40.40%
Current year-50.50%
1 week 14.64
Extreme 14.64
16.6
1 month 12.9
Extreme 12.9
16.6
Current year 12.9
Extreme 12.9
36
1 year 12.9
Extreme 12.9
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/25 Buy

Chief Executive Officer

6 0.0000%
4/9/25 Free

Chief Executive Officer

1,393 0.0040%
3/9/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-1.59%-5.10%-39.92%-15.53% 55.26M
-1.32%+1.33%+77.46%+41.17% 371B
-0.59%-2.84%+21.72%-19.35% 68.64B
-0.51%+4.59%+47.06%+168.63% 12.51B
-0.56%-9.06%-8.11%-8.78% 8.06B
+0.23%-1.59%-20.70%+6.13% 5.04B
0.00%-4.12%-31.60%+20.55% 4.51B
-0.35%-3.11%-33.77%+1.20% 3.07B
-1.00%-0.46%-5.37%+37.45% 2.53B
-0.50%-3.98%-24.35%-16.61% 2B
Average -0.62%-0.26%-1.76%+21.48% 47.73B
Weighted average by Cap. -1.14%+0.48%+63.54%+33.87%

Financials

2026 *2027 *
Net sales 19M 1.99M 1.71M 1.61M 1.47M 2.75M 188M 2.76M 7.37M 96.21M 7.46M 7.29M 310M 27M 2.82M 2.43M 2.28M 2.09M 3.9M 266M 3.92M 10.48M 137M 10.6M 10.37M 440M
Net income -375M -39.2M -33.73M -31.73M -28.99M -54.23M -3.7B -54.38M -146M -1.9B -147M -144M -6.12B -270M -28.27M -24.33M -22.89M -20.91M -39.12M -2.67B -39.23M -105M -1.37B -106M -104M -4.41B
Net Debt -105M -10.98M -9.44M -8.89M -8.12M -15.18M -1.04B -15.23M -40.74M -532M -41.21M -40.31M -1.71B -143M -14.95M -12.86M -12.1M -11.05M -20.68M -1.41B -20.74M -55.49M -724M -56.13M -54.9M -2.33B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
07/09/26 SEK 14.90 -1.59% 11,871
04/09/26 SEK 15.14 -1.69% 19,314
03/09/26 SEK 15.40 +1.05% 22,080
02/09/26 SEK 15.24 +1.20% 13,800
01/09/26 SEK 15.06 -4.08% 154,190
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!